Literature DB >> 12784116

Maintenance efficacy of divalproex in the prevention of bipolar depression.

Laszlo Gyulai1, Charles L Bowden, Susan L McElroy, Joseph R Calabrese, Frederick Petty, Alan C Swann, James C-Y Chou, Adel Wassef, Craig S Risch, Robert M A Hirschfeld, Charles B Nemeroff, Paul E Keck, Dwight L Evans, Patricia J Wozniak.   

Abstract

Breakthrough depression is a common problem in the treatment of bipolar disorder. Only one, recently published, double-blind, placebo-controlled trial has examined the efficacy of divalproex in the prevention of depressive episodes in bipolar patients. This report describes, in further detail, the findings from that trial of the effect of divalproex on multiple dimensions of depressive morbidity in bipolar disorder. A randomized, double-blind, parallel-group, multicenter study was conducted over a 52-week maintenance period. Bipolar I patients, who may have been treated with open-label lithium or divalproex and who met recovery criteria within 3 months of onset of an index manic episode, were randomized to maintenance treatment with divalproex, lithium, or placebo in a 2 : 1 : 1 ratio. Adjunctive paroxetine or sertraline for breakthrough depression was allowed in maintenance phase. Outcome measures were the rate of early discontinuation for depression, time to depressive relapse, proportion of patients with depressive relapse, mean change in Depressive Syndrome Scale score, proportion of patients receiving antidepressants, and time in the study. Among patients taking an antidepressant, a higher percentage of patients on placebo than divalproex discontinued early for depression. Patients who were previously hospitalized for affective episodes or took divalproex in the open period relapsed later on divalproex than on lithium during the maintenance period. Divalproex-treated patients had less worsening of depressive symptoms than lithium-treated patients during maintenance. Indices of severity of prestudy illness course predicted worse outcome in all treatment groups. Divalproex improved several dimensions of depressive morbidity and reduced the probability of depressive relapse in bipolar disorder, particularly in patients who had responded to divalproex when manic, and among patients with a more severe course of illness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784116     DOI: 10.1038/sj.npp.1300190

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  24 in total

1.  Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Treating Bipolar Disorder: For the Patient or Against the Illness?

Authors:  Alan C Swann
Journal:  Psychiatry (Edgmont)       Date:  2006-06

2.  Managing bipolar disorder from urgent situations to maintenance therapy.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 4.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

5.  [Acute and long-term treatment for bipolar depression].

Authors:  H Grunze; S Dargel
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

6.  Hippocratic psychopharmacology for Bipolar Disorder-An Expert's Opinion.

Authors:  S Nassir Ghaemi
Journal:  Psychiatry (Edgmont)       Date:  2006-06

Review 7.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

8.  Bipolar-I depression outpatient treatment quality and costs in usual care practice.

Authors:  Alisa B Busch; Richard G Frank; Gary Sachs
Journal:  Psychopharmacol Bull       Date:  2008

9.  Bipolar depression: clinically missed, pharmacologically mismanaged.

Authors:  Lisa C Lloyd; Giovanni Giaroli; David Taylor; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2011-10

Review 10.  Bipolar II disorder : epidemiology, diagnosis and management.

Authors:  Franco Benazzi
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.